CCR2 and cancer: CCL2-CCR2 signaling controls the supply of circulating inflammatory monocytes (Argyle and Kitamura, 2018) and inhibiting CCR2 keeps monocytes in bone marrow, reducing TAMs at cancer sites (Flores-Toro et al., 2020).